(Q40857084)

24 September 2017

1 reference

title

Relevance of the immune system in human urological malignancies: prospective for future clinical treatments (English)

1 reference

24 September 2017

Nouri AM

1

1 reference

PubMed ID

9610557

24 September 2017

Symes MO

series ordinal

2

1 reference

PubMed ID

9610557

24 September 2017

language of work or name

English

0 references

publication date

1 May 1998

1 reference

24 September 2017

1 reference

24 September 2017

51

1 reference

24 September 2017

5A Suppl

1 reference

24 September 2017

41-49

1 reference

HLA restriction of cell-mediated lysis of influenza virus-infected human cells

24 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900073-9

7 January 2021

Distribution of HLA class 1 antigens in normal human tissue and in mammary cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900073-9

7 January 2021

Down-regulation of class I HLA antigens and of the Epstein-Barr virus-encoded latent membrane protein in Burkitt lymphoma lines

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900073-9

7 January 2021

Expression of histocompatibility antigens and characterisation of mononuclear cell infiltrates in human renal cell carcinomas

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900073-9

7 January 2021

Loss of HLA-A,B,C allele products and lymphocyte function-associated antigen 3 in colorectal neoplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900073-9

7 January 2021

Selective and non-selective loss of immunoregulatory molecules (HLA-A,B,C antigens and LFA-3) in transitional cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900073-9

7 January 2021

Defective expression of MHC class I antigens is frequent in B-cell lymphomas of high-grade malignancy

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900073-9

7 January 2021

Class I histocompatibility antigen expression: a prognostic factor for aneuploid ovarian cancers

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900073-9

7 January 2021

Quantitation of MHC antigen expression on colorectal tumours and its association with tumour progression

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900073-9

7 January 2021

Paired tumour infiltrating lymphocyte (TIL) and tumour cell line from bladder cancer: a new approach to study tumour immunology in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900073-9

7 January 2021

Gene transfer into humans--immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900073-9

7 January 2021

Requirement of a thymus dependent immune response for BCG-mediated antitumor activity

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900073-9

7 January 2021

Rejection of transplantable AKR leukaemia cells following MHC DNA-mediated cell transformation

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900073-9

7 January 2021

Phase II study of interferon-gamma versus interleukin-2 and interferon-alpha 2b in metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900073-9

7 January 2021

Interferons and interleukins in metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900073-9

7 January 2021

HLA-class-I and -class-II expression on renal tumor xenografts and the relation to sensitivity for alpha-IFN, gamma-IFN and TNF.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900073-9

7 January 2021

Up-regulation of intercellular adhesion molecule 1 (ICAM-1) on human renal cell carcinoma cells by interleukin-4.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900073-9

7 January 2021

Expression of intercellular adhesion molecule-1 (ICAM-1) on renal-cell cancer: possible significance in host immune responses

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900073-9

7 January 2021

Unexplained spontaneous regression and alpha-interferon as treatment for metastatic renal carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900073-9

7 January 2021

The effect of alpha and gamma interferon on cell growth and histocompatibility antigen expression by human renal carcinoma cells in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900073-9

7 January 2021

Instability of expression of major histocompatibility antigens in fibroblasts expressing activated ras oncogene: constitutive and interferon-gamma induced class I and class II antigens in a series of clonal isolates of murine fibroblasts transformed

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900073-9

7 January 2021

Antitumor effects of human lymphoblastoid interferon on advanced renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900073-9

7 January 2021

Interferon in renal cell carcinoma. The UCLA experience.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900073-9

7 January 2021

Recombinant interleukin-2 in metastatic renal cell carcinoma—A European multicentre phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900073-9

7 January 2021

Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900073-9

7 January 2021

Second line therapy with low-dose subcutaneous interleukin-2 alone in advanced renal cancer patients resistant to interferon-alpha

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900073-9

7 January 2021

Phase II study of subcutaneous interleukin-2 in unselected patients with advanced renal cell cancer on an outpatient basis

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900073-9

7 January 2021

Subcutaneous recombinant interleukin-2 (rIL-2) in out-patients with metastatic renal cell carcinoma. Results of a multicenter SCAPP1 trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900073-9

7 January 2021

Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900073-9

7 January 2021

Interferon-γ is required in activation of macrophages for tumor cytotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900073-9

7 January 2021

The role of a gamma interferon-like lymphokine in the activation of T cells for expression of interleukin 2 receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900073-9

7 January 2021

Induction of HLA class-II antigen expression on human carcinoma cell lines by IFN-Gamma

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900073-9

7 January 2021

Phase I/II study of recombinant interferon gamma in advanced renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900073-9

7 January 2021

Successful treatment of metastatic renal cell carcinoma with a biologically active dose of recombinant interferon-gamma.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900073-9

7 January 2021

Combination therapy with interleukin-2 and alpha-interferon for the treatment of patients with advanced cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900073-9

7 January 2021

Phase I trial of high-dose bolus interleukin-2 and interferon alfa-2a in patients with metastatic malignancy

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900073-9

7 January 2021

Growth of tumor-infiltrating lymphocytes from human solid cancers: summary of a 5-year experience

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900073-9

7 January 2021

Interferon-alpha primed tumor-infiltrating lymphocytes combined with interleukin-2 and interferon-alpha as therapy for metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900073-9

7 January 2021

Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900073-9

7 January 2021

Immunochemotherapy for metastatic renal cell carcinoma using a regimen of interleukin-2, interferon-alpha and 5-fluorouracil

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900073-9

7 January 2021

Helper T cells infiltrating human renal cell carcinomas have the phenotype of activated memory-like T lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900073-9

7 January 2021

Signals and signs for lymphocyte responses

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900073-9

7 January 2021

Dendritic antigen-presenting cells from the peripheral blood of renal-cell-carcinoma patients

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900073-9

7 January 2021

Differential immune reactivity of tumour-intrinsic and peripheral-blood lymphocytes against autoplastic colorectal carcinoma cells

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900073-9

7 January 2021

The correlation of T1 bladder tumour history with prognosis and follow-up requirements

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900073-9

7 January 2021

Superficial bladder cancer: progression and recurrence

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900073-9

7 January 2021

Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900073-9

7 January 2021

Intravesical Evans strain BCG therapy: quantitative immunohistochemical analysis of the immune response within the bladder wall

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900073-9

7 January 2021

Detection of interleukin 2 in the urine of patients with superficial bladder tumors after treatment with intravesical BCG

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900073-9

7 January 2021

Changes in urinary cytokines and soluble intercellular adhesion molecule-1 (ICAM-1) in bladder cancer patients after bacillus Calmette-Guérin (BCG) immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900073-9

7 January 2021

T-cell subsets required for intravesical BCG immunotherapy for bladder cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900073-9

7 January 2021

HLA-DR expression by high grade superficial bladder cancer treated with BCG.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900073-9

7 January 2021

Local immunotherapy of superficial bladder cancer by intravesical instillation of recombinant interleukin-2

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900073-9

7 January 2021

The use of immunologically competent cells in the treatment of cancer: experiments with a transplantable mouse tumour

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900073-9

7 January 2021

Transfer of adoptive immunity by intra-arterial injection of tumor-immune pig lymph node cells: treatment of recurrent urinary bladder carcinoma after radical radiotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900073-9

7 January 2021

SELECTIVE LOSS OF HLA-A,B,C LOCUS PRODUCTS IN COLORECTAL ADENOCARCINOMA

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900073-9

7 January 2021

Evaluation of the effect of continuous infusion recombinant interleukin-2 (bioleukin) on peripheral blood leucocytes of patients with terminal malignancy

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900073-9

7 January 2021

Clinical and immunological effect of intravesical interleukin-2 on superficial bladder cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900073-9

7 January 2021

Comparison of immunological changes between subcutaneous and intravenous route of administration of IL-2 in cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900073-9

7 January 2021

Epidermal growth factor-induced protection of tumour cell susceptibility to cytolysis

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900073-9

7 January 2021

Interaction between major histocompatibility complex antigens and epidermal growth factor receptors on human cells

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900073-9

7 January 2021

Serum interleukin-6 in relation to acute-phase reactants and survival in patients with renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900073-9

7 January 2021

MHC-dependent cytolysis of autologous tumor cells by lymphocytes infiltrating urothelial carcinomas

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900073-9

7 January 2021

Expression of antitumor response. Role of attachment and viability of bacillus Calmette-Guérin to bladder cancer cells

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900073-9

7 January 2021

Effects of bacillus Calmette-Guerin and interferon-alpha-2B on human bladder cancer in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900073-9

7 January 2021

10.1016/S0090-4295(98)00073-9

Identifiers

DOI

1 reference

24 September 2017

1 reference

PubMed ID

9610557